Argipressin: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: April 10, 2026🚩 Report this page

Argipressin

Vasopressin and Analogues

GB MHRA

Drug class: Vasopressin and Analogues
Availability: See label
Markets covered: 1
Products on record: 2

Overview

Argipressin is an active pharmaceutical ingredient in the Vasopressin and Analogues group (H01BA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	2	April 10, 2026

GBUnited Kingdom· MHRA

2 products

Uses

GBOfficial regulatory label· revised April 4, 2025[1]

Argipressin AOP is indicated in adults for the treatment of diabetes insipidus, when this is not of nephrogenic origin and control of bleeding from oesophageal varices.

How to take

Sources & citations

[1]MHRA (UK) · PL213440024 · revised April 4, 2025

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised April 4, 2025[1]

The following undesirable effects have been observed and reported during treatment with Argipressin with the following frequency: The undesirable effects are listed below by organ class and the following frequency convention: Very common: (≥1/10) Common: (≥1/100, <1/10) Uncommon: (≥1/1,000, <1/100) Rare: ((≥1/10,000, <1/1,000) Very rare: (<1/10,000), Not known – frequency cannot be estimated from the available data.
The frequency of the following side effects is not known. Immune system disorders • Hypersensitivity • anaphylaxis Metabolism and nutrition disorders • hyperhydration / water intoxication Nervous system disorders • headache • vertigo • tremor Cardiac disorder • chest pain due to angina • cardiac arrest Vascular disorders • peripheral ischaemia • pallor • hypertension Respiratory, thoracic and mediastinal disorders • bronchospasm Gastrointestinal disorders • flatulence • nausea • vomiting • diarrhoea • abdominal pain Skin and subcutaneous tissue disorders • gangrene • hyperhidrosis • urticaria Renal and urinary disorders • fluid retention General disorders and administration site conditions • non-cardiac chest pain Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised April 4, 2025[1]

Argipressin should not be used in patients with systemic hypertension or vascular disease, especially disease of the coronary arteries, except with extreme caution. In such patients, even small doses may precipitate pain, and with larger doses, the possibility of myocardial infarction should be considered.
If this drug must be used in patients with peripheral vascular disease then the skin should be observed carefully for signs of ischaemia. Argipressin may produce water intoxication. The early signs of drowsiness, listlessness, and headaches should be recognised to prevent terminal coma and convulsions.
Adjustment of dosage in cases immediately post-hypophysectomy should be controlled on the basis of measurements of urine osmolality. Argipressin should be used cautiously in the presence of epilepsy, migraine, asthma, heart failure, or any state in which a rapid addition to extracellular water may produce hazard for an already overburdened system.
Chronic nephritis with nitrogen retention contraindicates the use of argipressin injection until reasonable nitrogen blood levels have been attained.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations